Table 2.
Univariable and multivariable analyses for RFS.
| Variable | Univariable | Multivariable | ||||
|---|---|---|---|---|---|---|
| HR | 95% CIs | p-Value | HR | 95% CIs | p-Value | |
| Age ≤ 50 years (ref. > 50 years) | 1.24 | 0.813–1.893 | 0.318 | |||
| TP53 mutation (ref. TP53 wild-type) | 1.669 | 1.058–2.635 | 0.028 | 1.29 | 1.008–1.832 | 0.046 |
| Histologic grade III (ref. HG I-II) | 1.123 | 0.730–1.730 | 0.597 | |||
| HR positive (ref. HR negative) # | 1.234 | 0.781–1.950 | 0.367 | |||
| HER2 positive (ref. HER2 negative) | 0.718 | 0.439–1.172 | 0.185 | |||
| LVI present (ref. LVI absent) # | 2.604 | 1.686–4.021 | <0.001 | 2.366 | 1.495–3.747 | <0.001 |
| Ki67 high (≥20%) (ref. Ki67 < 20%) | 1.829 | 1.198–2.790 | 0.005 | 1.607 | 1.030–2.506 | 0.037 |
| Tumor > 2 cm (ref. Tumor ≤ 2 cm) * | 1.743 | 1.115–2.724 | 0.015 | 1.355 | 0.843–2.178 | 0.209 |
| Nodal involvement (ref. Node-negative) * | 1.3 | 0.839–2.014 | 0.241 | |||
| BCS (ref. Mastectomy) | 1.383 | 0.903–2.117 | 0.136 | |||
| HER2-targeted therapy (ref. no treatment) | 0.774 | 0.455–1.316 | 0.343 | |||
# Patients without definite data were excluded. * Patients who underwent neoadjuvant chemotherapy were excluded. Abbreviations, HR, hazard ratio, CIs; confidence intervals, HR, hormone receptor, HER2; human epidermal growth factor receptor 2, LVI; lymphovascular invasion, BCS; breast-conserving surgery.